Novo research director on obesity study: "We couldn't have hoped for a better start"
The first phase III study of Novo Nordisk's drug semaglutid in obesity exceeded the company's expectations and, according to research director Mads Krogsgaard Thomsen, proves that obesity is a chronic illness which needs to be treated like diabetes or high blood pressure.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
On Wednesday evening, Novo Nordisk could reveal phase III results from trials of the company's all-round drug semaglutid as a treatment for obesity - a widespread disease area, which Novo Nordisk wants to be the first pharmaceutical company to seriously take on.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
